SAMATASVIR

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C47H48N8O6S2
Molecular Weight	885.064
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C2=NC3=CC=C(C=C3N2)C4=CSC5=C4SC=C5C6=CC=C(C=C6)C7=CN=C(N7)[C@@H]8CCCN8C(=O)[C@H](NC(=O)OC)C9=CC=CC=C9

InChI

InChIKey=ATOLIHZIXHZSBA-BTSKBWHGSA-N

InChI=1S/C47H48N8O6S2/c1-26(2)38(52-46(58)60-3)44(56)55-21-9-13-37(55)43-49-33-19-18-30(22-34(33)50-43)32-25-63-40-31(24-62-41(32)40)27-14-16-28(17-15-27)35-23-48-42(51-35)36-12-8-20-54(36)45(57)39(53-47(59)61-4)29-10-6-5-7-11-29/h5-7,10-11,14-19,22-26,36-39H,8-9,12-13,20-21H2,1-4H3,(H,48,51)(H,49,50)(H,52,58)(H,53,59)/t36-,37-,38-,39+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C47H48N8O6S2
Molecular Weight	885.064
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24434503 | https://clinicaltrials.gov/ct2/show/NCT01508156

Samatasvir (also known as IDX 719) was developed by Idenix Pharmaceuticals as a pan-genotypic inhibitor of the hepatitis C (HCV) non-structural protein 5A (NS5A). This drug was studied in phase II clinical trials for the treatment of Hepatitis C, and Chronic Hepatitis C Infection. However, the development of samatasvir was discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.	2014 Aug	24867983
A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4.	2014 May	24434503

Patents

Sample Use Guides

In Vivo Use Guide

Treatment-naive participants infected with HCV genotype (GT) 1, GT2, or GT3 take Samatasvir (IDX719) (1 mg - 100 mg) or matching placebo as either 1 single dose or as 7 daily doses.

Route of Administration: Oral

In Vitro Use Guide

Samatasvir was effective and selective against infectious hepatitis C virus (HCV) and replicons, with 50% effective concentrations (EC50s) falling within a tight range of 2 to 24 pM in genotype 1 through 5 replicons and with a 10-fold EC50 shift in the presence of 40% human serum in the genotype 1b replicon. The EC90/EC50 ratio was low (2.6). A 50% cytotoxic concentration (CC50) of >100 μM provided a selectivity index of >5 × 10(7).

Substance Class	Chemical Created by `admin` on `Sat Dec 16 01:57:02 GMT 2023` Edited by `admin` on `Sat Dec 16 01:57:02 GMT 2023`
Record UNII	21P699C5FC
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SAMATASVIR

Official Name

English

IDX-18719

Code

English

Samatasvir [WHO-DD]

Common Name

English

CARBAMIC ACID, N-((1R)-2-((2S)-2-(5-(4-(6-(2-((2S)-1-((2S)-2-((METHOXYCARBONYL)AMINO)-3-METHYL-1-OXOBUTYL)-2-PYRROLIDINYL)-1H-BENZIMIDAZOL-6-YL)THIENO(3,2-B)THIEN-3-YL)PHENYL)-1H-IMIDAZOL-2-YL)-1-PYRROLIDINYL)-2-OXO-1-PHENYLETHYL)-, METHYL ESTER

Systematic Name

English

samatasvir [INN]

Common Name

English

SAMATASVIR [USAN]

Common Name

English

IDX18719

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C281